1-7 of 7
Byoung Chul Cho
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Jessica J. Lin, Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson, Benjamin Besse, D. Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola W. Zhu, Enriqueta Felip, Byoung Chul Cho, Luc Friboulet, Aaron N. Hata, Henry E. Pelish, Alexander Drilon
Journal: Cancer Discovery
Cancer Discov (2024) 14 (12): 2367–2386.
https://doi.org/10.1158/2159-8290.CD-24-0231
Published: 02 December 2024
View articletitled, NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Open the PDF for NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations in another window
Includes: Supplementary data
Journal Articles

D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Jing Zhang, Sun Min Lim, Mi Ra Yu, Cheng Chen, Jia Wang, Wenqian Wang, Haopeng Rui, Jingtao Lu, Shun Lu, Tony Mok, Zhi Jian Chen, Byoung Chul Cho
Journal: Cancer Discovery
Cancer Discov (2024) 14 (9): 1675–1698.
https://doi.org/10.1158/2159-8290.CD-24-0006
Published: 04 September 2024
View articletitled, D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Open the PDF for D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities in another window
Includes: Supplementary data
Journal Articles

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Ryan J. Hartmaier, Aleksandra A. Markovets, Myung Ju Ahn, Lecia V. Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee, Wu-Chou Su, Dariusz M. Kowalski, Sergey Orlov, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne
Journal: Cancer Discovery
Cancer Discov (2023) 13 (1): 98–113.
https://doi.org/10.1158/2159-8290.CD-22-0586
Published: 09 January 2023
View articletitled, Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
Open the PDF for Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON in another window
Includes: Supplementary data
Journal Articles

Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC

Sun Min Lim, Chang Gon Kim, Jii Bum Lee, Byoung Chul Cho
Journal: Cancer Discovery
Cancer Discov (2022) 12 (1): 16–19.
https://doi.org/10.1158/2159-8290.CD-21-1429
Published: 12 January 2022
View articletitled, Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC
Open the PDF for Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC in another window
Journal Articles

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Jiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, Seo-Yoon Jeong, Jae-Hwan Kim, Kyoung-Ho Pyo, Chae-Won Park, Seong Gu Heo, Mi Ran Yun, Sangbin Lim, Sun Min Lim, Min Hee Hong, Hye Ryun Kim, Meena Thayu, Joshua C. Curtin, Roland E. Knoblauch, Matthew V. Lorenzi, Amy Roshak, Byoung Chul Cho
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (8): 1194–1209.
https://doi.org/10.1158/2159-8290.CD-20-0116
Published: 03 August 2020
View articletitled, Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
Open the PDF for Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC in another window
Includes: Supplementary data
Journal Articles

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Alexander Drilon, Siqing Fu, Manish R. Patel, Marwan Fakih, Ding Wang, Anthony J. Olszanski, Daniel Morgensztern, Stephen V. Liu, Byoung Chul Cho, Lyudmila Bazhenova, Cristina P. Rodriguez, Robert C. Doebele, Antoinette Wozniak, Karen L. Reckamp, Tara Seery, Petros Nikolinakos, Zheyi Hu, Jennifer W. Oliver, Denise Trone, Katherine McArthur, Rupal Patel, Pratik S. Multani, Myung-Ju Ahn
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (3): 384–395.
https://doi.org/10.1158/2159-8290.CD-18-0839
Published: 01 March 2019
View articletitled, A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Open the PDF for A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105 in another window
Includes: Supplementary data
Journal Articles

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung-Ju Ahn, D. Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K. Lim, Shanna Stopatschinskaja, David M. Hyman, Robert C. Doebele, J. Jean Cui, Alice T. Shaw
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (10): 1227–1236.
https://doi.org/10.1158/2159-8290.CD-18-0484
Published: 02 October 2018
View articletitled, Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Open the PDF for Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations in another window
Includes: Supplementary data